A new version of the Inserm website is now online. Designed and created by Inserm and the W* agency, the site has been rethought, not only in terms of graphics, but also from an ergonomic, technical, and editorial perspective. Objective: to consolidate the role of the Institute as an outlet for information on health and biomedical research, and to enhance the visibility of Inserm on the web.
In terms of health, men and women are not painted with the same brush. This is due not just to their biology but also to social, cultural and economic reasons, which are not always taken into account. Gender stereotypes influence medical practices, research, teaching and patient behaviors, leading to situations of gender inequality and discrimination in the management of and access to healthcare.
La création d'Accélérateurs de Recherche Technologique est une priorité du plan d'orientation stratégique de l'Inserm. Ce 12 octobre 2017, l'Inserm inaugure son deuxième ART consacré à la "Bioimpression 3D" à Bordeaux. Il s'agit de la seule unité technologique utilisant les trois principales technologies de l'impression biologique en 3D, à savoir : le laser, le jet d'encre, et la micro-extrusion. Au sein de l'ART se côtoieront chercheurs et ingénieurs, afin...
Space is an extraordinary laboratory for medicine and medical research on Earth. That is why Inserm and the CNES have been working together for more than a year[1] to accelerate research progress to improve the health of all of us. The presence of Thomas Pesquet, French astronaut from the European Space Agency (ESA), on board the International Space Station (ISS) for 6 months gave rise to many experiments, the...
The Vision Institute (Inserm, Université Pierre et Marie Curie (UPMC), National Center for Scientific Research (CNRS)) via the Fondation Voir & Entendre has signed a contract with the United States Defense Advanced Research Projects Agency (DARPA), which could ultimately represent $ 25 million. With the help of an international consortium, researchers from Inserm, CNRS and UPMC, working within the Vision Institute, want to develop a system capable of restoring...
The current migratory crisis in Europe shows the necessity to have solid scientific data to help public authorities take important decisions, in the context of emergencies and varied political situations. In response to these concerns, Inserm and the CNRS have enlisted five teaching and research institutions (Ined - French National Institute for demographic studies, IRD - French Institute for Development Research, Université Paris 1 Panthéon-Sorbonne, EHESS - School for...
The European Patents Office (EPO) has just published its annual rankings: For the first time, Inserm has taken the top ranking for applicants in the pharmaceutical sector ahead of the big industrial companies and can confirm at the same time its top place as a European academic applicant in biomedical research.
Prof. François Dabis has just been appointed Director of ANRS, an autonomous agency of Inserm, by the Ministers responsible for Research and Health, on the proposal of the Chairman and CEO of Inserm. A physician, academic and internationally renowned researcher, Prof. Dabis specialises in epidemiology and public health. He succeeds Prof. Jean-François Delfraissy, the new President of the National Consultative Ethics Committee.
Paris, March 21st, 2017 – Stimunity, Institut Curie and Inserm are pleased to announce that the company has signed an exclusive worldwide license agreement on two key patents that cover Stimunity’s core technology VLP-cGAMP to develop new drugs in immuno-oncology.
L’Inserm se classe 9e dans le « Top 25 Global Innovators - Government » Reuters/Clarivate, qui évalue la capacité d’innovation des organisations publiques en fonction de l’impact de leur production scientifique et de leurs brevets.